BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30
• 31

• 

  Fibrobiologics
• 

  Spanios
• 

  Orano Med
• 

  Infectious disease

  J&J Discontinues Phase II Dengue Study as it Retreats from Infectious Disease

  J&J has recently pulled back from the infectious diseases space, including winding down R&D activity in this area in August 2023.

  October 7, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cancer

  TIGITs Trend Upward After iTeos/GSK Present Positive Data at ESMO

  After several high-profile failures, including BMS’ $1.5B breakup with Agenus, anti-TIGIT therapies are generating cautious optimism.

  October 7, 2024

   · 

  6 min read

   · 

  Gail Dutton
• 

  Weight loss

  Can CB1 Inhibitors Make a Comeback in Obesity?

  After psychological side effects doomed the first generation of cannabinoid receptor 1–targeting drugs for weight loss, Novo Nordisk, Corbus Pharmaceuticals and Skye Bioscience are betting that a new mechanism of action will improve the safety profile.

  October 7, 2024

   · 

  6 min read

   · 

  Jill Drachenberg
• 

  Regulatory

  Kezar’s Lupus Trial Paused After Four Patient Deaths

  The clinical hold doesn’t cover its drug’s Investigational New Drug application for autoimmune hepatitis, for which the Phase IIa PORTOLA trial is ongoing.

  October 7, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cardiovascular disease

  AstraZeneca Puts $2B On The Line for Preclinical Heart Disease Drug

  For an exclusive license to the preclinical Lp(a) disruptor, AstraZeneca is paying CSPC Pharmaceutical Group $100 million upfront and offering up to $1.92 billion in regulatory and commercial milestones.

  October 7, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

  October 7, 2024

   · 

  6 min read
• Press Releases

  Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

  October 7, 2024

   · 

  1 min read